Epidemiology of varicella-zoster virus in England and Wales

Journal of Medical Virology

Volumn 70, Issue SUPPL. 1, 2003, Pages

  Brisson, M ^a,b,c   Edmunds, W J ^a,b  

^a Immunisation Division   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Case fatality; Epidemiology; Hospitalisation; Incidence rate; Inpatient days; Morbidity; Varicella; VZV; Zoster

Indexed keywords

CHICKENPOX VACCINE;

ADOLESCENT; ADULT; AGED; CHICKENPOX; CHILD; CONFERENCE PAPER; DEATH CERTIFICATE; EPIDEMIOLOGICAL DATA; GENERAL PRACTICE; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; NEWBORN; TREATMENT PLANNING; UNITED KINGDOM; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENGLAND; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; WALES;

HUMAN HERPESVIRUS 3;

EID: 0037401604     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10313     Document Type: Conference Paper

References (37)

1. Bramley JC, Jones IG. 2000. Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health 3:282-287.
2. Brisson M, Edmunds WJ. 2002. The cost-effectiveness of varicella zoster virus (VZV) vaccination in Canada. Vaccine 20:1113-1125.
3. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. 2000. Modelling the impact of immunisation on the epidemiology of varicella zoster virus. Epidemiol Infect 125:651-669.
4. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G. 2001. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127:305-314.
5. Brisson M, Gay N, Edmunds WJ, Andrews NJ. 2002. Exposure to Varicella Boosts Immunity to Herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine 20:2500-2507.
6. Centers for Disease Control and Prevention. 1996. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Wkly Rep 45:1-36.
7. Choo PW, Donahue JG, Manson JE, Platt R. 1995. The epidemiology of varicella and its complications. J Infect Dis 172:706-712.
8. Coplan P, Black S, Rojas C, Shinefield H, Ray P, Lewis E, Guess H. 2001. Incidence and hospitalisation rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J 20:641-645.
9. de Moragas JM, Kierland RR. 1957. The outcome of patients with herpes zoster. AMA Arch of Derm 7:193-196.
10. Deguen S, Chau NP, Flahaut A. 1998. Epidemiology of Chickenpox in France (1991-1995). J Epidemiol Community Health 52(Suppl 1): 46S-49S.
11. Domingo JD, Ridao M, Latour J, Ballester A, Morant A. 1999. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17:1306-1311.
12. Fairley CK, Miller E. 1996. Varicella-zoster virus epidemiology: a changing scene? J Infect Dis 174(Suppl 3):S314-S319.
13. Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. 1994. Agespecific incidence of chickenpox. Public Health Rep 109:750-755.
14. Fleming DM. 1999. Weekly returns service of the Royal College of General Practitioners. Commun Dis Public Health 2:96-100.
15. Garnett GP, Grenfell BT. 1992. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes-zoster. Epidemiol Infect 108:513-528.
16. Gil A, Oyaguez I, Carrasco P, Gonzalez A. 2001. Epidemiology of primary varicella hospitalizations in Spain. Vaccine 20:295-298.
17. Guess HA, Broughton DD, Melton LJ, Kurland LT. 1984. Chickenpox hospitalisations among residents of Olmsted Country, Minnesota, 1962 through 1981. Am J Dis Child 138:1055-1057.
18. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. 1994. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 140:81-104.
19. Health Canada Proceedings of the National Varicella Consensus Conference. 1999. Canada Communicable Disease Report 25(Suppl): 1-29.
20. Hope-Simpson RE. 1965. The nature of Herpes-zoster: a long-term study and a new hypothesis. Proc R Soc Med 58:9-20.
21. Hope-Simpson RE. 1975. Postherpetic neuralgia. J R Coll Gen Pract 25:571-575.
22. Lin F, Hadler JL. 2000. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 181:1897-1905.
23. McCormick A, Fleming D, Charlton J. 1995. Morbidity statistics from general practice: Fourth National Study 1991-1992. London: OPCS.
24. Meyer PA, Seward JF, Jumaan AO, Wharton M. 2000. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 182:383-390.
25. Office for National Statistics. Twentieth century mortality. 2000. CDROM. London: HMSO.
26. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. 1999. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 319:1462-1467.
27. Paparatti UL, Arpinelli F, Visona G. 1999. Herpes zoster and its complications in Italy: an observational survey. J Infect 38:116-120.
28. Ragozzino MW, Melton LJ, Kurland LT, CHU CP, Perry HO. 1982. Population-based study of herpes zoster and its sequelae. Medicine 61:310-316.
29. Rooney C, Devis T. 1996. Mortality trends by cause of death in England and Wales 1980-94: the impact of introducing automated cause coding and related changes in 1993. Pop Trends 86:29-35.
30. Ross AM, Fleming DM. 2000. Chickenpox increasingly affects preschool children. Commun Dis Public Health 3:213-215.
31. Schuette MC, Hethcote HW. 1999. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 61:1031-1064.
32. Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. 1999a. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 49:763-779.
33. Scuffham PA, Lowin AV, Burgess MA. 1999b. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18:407-415.
34. Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. 1975. Development of a live attenuated varicella vaccine. Biken J 18: 25-33.
35. Thomas SL, Wheeler JG, Hall AJ. 2001. Risk factors for herpes zoster in immunocompetent adults. J Epid Comm Health 55(Suppl):A29 (Abstract 108).
36. Wharton M. 1996. The epidemiology of varicella-zoster virus infections. Infect Dis Clin N Am 10:571-581.
37. Wharton M, Fehrs LJ, Cochi SL, et al. 1990. Health impact of varicella in the 1980s (abstract). Program and abstracts of the 30th Interscience Conference on Amtimicromial Agents and Chemotherapy, Atlanta, Georgia, October 21-24, 1990.